This study was published in Circulation 2000 Oct 10;102(15):1748-54
Study title and authors:
Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ.
University of Alberta Hospitals, Edmonton, Alberta, Canada. teok@fhs.mcmaster.ca
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/11023927
One of the aims of this long-term, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the effects of simvastatin in patients with normal cholesterol levels and with detectable plaque build up in at least three major coronary artery segments. The study lasted for four years and included a total of 460 patients: 230 received simvastatin and 230, a placebo.
The study found:
(a) The patients receiving simvastatin had a 117% increased risk of death compared to the patients receiving placebo.
(b) The patients receiving simvastatin had a 76% increased risk of cardiac death compared to the patients receiving placebo.
(c) The patients receiving simvastatin had a 225% increased risk of non-cardiac death compared to the patients receiving placebo.
(d) The patients receiving simvastatin had a 9% increased risk of a heart attack compared to the patients receiving placebo.
(e) The patients receiving simvastatin had a 78% increased risk of cancer compared to the patients receiving placebo.
The data from the study reveals that statins are associated with higher death rates, higher cardiac death rates and increased risk of cancer.
